| Initial genome sequencing and analysis of multiple myeloma MA Chapman, MS Lawrence, JJ Keats, K Cibulskis, C Sougnez, ... Nature 471 (7339), 467-472, 2011 | 1742 | 2011 |
| Lenalidomide after stem-cell transplantation for multiple myeloma PL McCarthy, K Owzar, CC Hofmeister, DD Hurd, H Hassoun, ... New England Journal of Medicine 366 (19), 1770-1781, 2012 | 1361 | 2012 |
| Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy JG Lohr, P Stojanov, SL Carter, P Cruz-Gordillo, MS Lawrence, D Auclair, ... Cancer cell 25 (1), 91-101, 2014 | 1132 | 2014 |
| TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes JS Welch, AA Petti, CA Miller, CC Fronick, M O’Laughlin, RS Fulton, ... New England Journal of Medicine 375 (21), 2023-2036, 2016 | 850 | 2016 |
| A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma DS Siegel, T Martin, M Wang, R Vij, AJ Jakubowiak, S Lonial, S Trudel, ... Blood, The Journal of the American Society of Hematology 120 (14), 2817-2825, 2012 | 821 | 2012 |
| Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia SO Ciurea, MJ Zhang, AA Bacigalupo, A Bashey, FR Appelbaum, ... Blood, The Journal of the American Society of Hematology 126 (8), 1033-1040, 2015 | 695 | 2015 |
| Oral selinexor–dexamethasone for triple-class refractory multiple myeloma A Chari, DT Vogl, M Gavriatopoulou, AK Nooka, AJ Yee, CA Huff, ... New England Journal of Medicine 381 (8), 727-738, 2019 | 636 | 2019 |
| Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy UH Gandhi, RF Cornell, A Lakshman, ZJ Gahvari, E McGehee, ... Leukemia 33 (9), 2266-2275, 2019 | 552 | 2019 |
| Efficacy of venetoclax as targeted therapy for relapsed/refractory t (11; 14) multiple myeloma S Kumar, JL Kaufman, C Gasparetto, J Mikhael, R Vij, B Pegourie, ... Blood, The Journal of the American Society of Hematology 130 (22), 2401-2409, 2017 | 542 | 2017 |
| A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma AJ Jakubowiak, D Dytfeld, KA Griffith, D Lebovic, DH Vesole, S Jagannath, ... Blood, The Journal of the American Society of Hematology 120 (9), 1801-1809, 2012 | 521 | 2012 |
| Driver fusions and their implications in the development and treatment of human cancers Q Gao, WW Liang, SM Foltz, G Mutharasu, RG Jayasinghe, S Cao, ... Cell reports 23 (1), 227-238. e3, 2018 | 516 | 2018 |
| SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution CA Miller, BS White, ND Dees, M Griffith, JS Welch, OL Griffith, R Vij, ... PLoS computational biology 10 (8), e1003665, 2014 | 503 | 2014 |
| International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 464 | 2016 |
| Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study PG Richardson, DS Siegel, R Vij, CC Hofmeister, R Baz, S Jagannath, ... Blood, The Journal of the American Society of Hematology 123 (12), 1826-1832, 2014 | 464 | 2014 |
| Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation I Pusic, SY Jiang, S Landua, GL Uy, MP Rettig, AF Cashen, P Westervelt, ... Biology of Blood and Marrow Transplantation 14 (9), 1045-1056, 2008 | 445 | 2008 |
| A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia GL Uy, MP Rettig, IH Motabi, K McFarland, KM Trinkaus, LM Hladnik, ... Blood, The Journal of the American Society of Hematology 119 (17), 3917-3924, 2012 | 438 | 2012 |
| Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma S Lonial, R Vij, JL Harousseau, T Facon, P Moreau, A Mazumder, ... Journal of clinical oncology 30 (16), 1953-1959, 2012 | 405 | 2012 |
| Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies D Siegel, T Martin, A Nooka, RD Harvey, R Vij, R Niesvizky, AZ Badros, ... Haematologica 98 (11), 1753, 2013 | 391 | 2013 |
| Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction SM Devine, R Vij, M Rettig, L Todt, K McGlauchlen, N Fisher, H Devine, ... Blood, The Journal of the American Society of Hematology 112 (4), 990-998, 2008 | 370 | 2008 |
| CD56bright NK cells exhibit potent antitumor responses following IL-15 priming JA Wagner, M Rosario, R Romee, MM Berrien-Elliott, SE Schneider, ... The Journal of clinical investigation 127 (11), 4042-4058, 2017 | 342 | 2017 |
